Please select the option that best describes you:
What is the role for maintenance lenalidomide in elderly patients with DLBCL?
Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?
Answer from: Medical Oncologist at Academic Institution
The REMARC study was a phase III trial of maintenance with lenalidomide versus placebo in patients aged 60-80 years old who were in a PR or CR after RCHOP for newly diagnosed DLBCL (Thieblemont et al. JCO 35:2471-2481, 2017.). The results of this large study (650pts) with a median follow up of over...
Sign in or Register to read more